# Repurposing Valsartan May Protect Against Pulmonary Hypertension

> **NCT06053580** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 60 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension
- Right Heart Failure
- Right Ventricular Dysfunction
- Pulmonary Vascular Disorder

## Interventions

- **DRUG:** Valsartan 40 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06053580
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-28
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06053580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06053580, "Repurposing Valsartan May Protect Against Pulmonary Hypertension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06053580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*